Calcium channel

Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio

Retrieved on: 
Thursday, January 18, 2024
AATD, FTD, Chord, Patient, Chronic obstructive pulmonary disease, Cirrhosis, Fibrosis, Oligonucleotide, Emphysema, RNA, Mouse, RNA editing, AAT, COPD, Dicarboxylic acid, De novo, Conference, Central nervous system, Calcium channel, Piz, Protein, Inflammation, ADAR, Adenosine deaminase, Machine learning, Customization, Genetic disorder, ALS, Liver disease, Nav1.7, Vaccine

AATD can lead to severe progressive lung disease, including emphysema and chronic obstructive pulmonary disease (COPD), and severe liver disease leading to inflammation, cirrhosis, and fibrosis.

Key Points: 
  • AATD can lead to severe progressive lung disease, including emphysema and chronic obstructive pulmonary disease (COPD), and severe liver disease leading to inflammation, cirrhosis, and fibrosis.
  • Korro’s proprietary RNA editing platform, OPERA™, integrates a deep understanding of adenosine deaminase acting on RNA (ADAR) enzymology with expertise in oligonucleotide chemistry, machine learning optimization of oligonucleotides and fit-for-purpose delivery.
  • CHORDs™, or Customized High-fidelity Oligonucleotides for RNA Deamination, are single-stranded, anti-sense oligonucleotides designed to have high target efficiency and specificity by leveraging the pillars of OPERA.
  • The replay is available for 30 days following the January 9, 2024 conclusion of the presentation.

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

Retrieved on: 
Monday, October 30, 2023
Neoplasm, PDUFA, Food, Dysgeusia, Rash, Vitamin, Vonoprazan, Abdomen, Clarithromycin, Liver, Chills, Pain, Hypersensitivity, Infection, Allergy, Azithromycin, Rilpivirine, Diarrhea, Liver disease, Tablet, Medicine, Genetically modified bacteria, Drug, Safety, Patient, Chronic pain, DUAL, Catalent, History, Weight loss, Colchicine, GERD, Helicobacter pylori, Fever, Calcium channel, Common, PAS, Jaundice, CGA, Abdominal pain, FDA, Infectious mononucleosis, Headache, Aes, Skin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Candidiasis, Erythromycin, Urine, Hypertension, Breast milk, Blood, AE, Pharmaceutical industry, Vaccine, Soft drink, Teahouse, Antibiotics, Medicinal plants, Dietary supplement, Birth control, Amoxicillin, Emtricitabine/rilpivirine/tenofovir

The full Prescribing Information for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can be found here.

Key Points: 
  • The full Prescribing Information for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can be found here.
  • VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) are co-packaged prescription medicines for the treatment of a Helicobacter pylori (H. pylori) bacterial infection in adults.
  • It is not known if VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are safe and effective in children.
  • Stop taking VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK if you are diagnosed with mononucleosis and call your doctor right away.

Cytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions

Retrieved on: 
Friday, October 6, 2023
III, Research and development, Guideline, Calcium channel, Female, Disopyramide, VO2, N-terminal prohormone of brain natriuretic peptide, Obstruction, SD, LVEF, NYHA, Safety, Exercise, Patient, SAN, Cytokinetics, Medical Center, LVOT, Lahey Hospital & Medical Center, Pharmaceutical industry, HCM

SEQUOIA-HCM enrolled a total of 282 patients, with one third from the United States, one half from Europe and Israel, and the remainder from China.

Key Points: 
  • SEQUOIA-HCM enrolled a total of 282 patients, with one third from the United States, one half from Europe and Israel, and the remainder from China.
  • Background medical therapy consisted of beta-blockers (61%), calcium channel blockers (26.6%), and disopyramide (12.8%); combination background therapy was permitted.
  • At baseline, 75.9% of patients were NYHA functional class II, 23.8% were functional class III, and 0.4% were functional class IV.
  • Key baseline characteristics that remain blinded include left ventricular ejection fraction (LVEF), resting and Valsalva LVOT-G, and NT-proBNP.

Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina

Retrieved on: 
Wednesday, August 16, 2023
Moyamoya disease, Additive effect, Prevalence, Angina, Calcium channel, Heart failure with preserved ejection fraction, Professor, Patient, Hemodynamics, Physician, MRCP, Pharmaceutical industry

BOSTON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company dedicated to developing innovative therapies designed to improve patient symptoms and function by enhancing cellular energetics, today announced that it has completed enrollment in the IMPROVE-ISCHEMIA Phase 2 placebo-controlled clinical trial of the investigational therapy, ninerafaxstat, in patients with stable angina. Imbria expects to report topline results from this trial in the fourth quarter of 2023.

Key Points: 
  • Imbria expects to report topline results from this trial in the fourth quarter of 2023.
  • “The randomized, placebo-controlled IMPROVE-ISCHEMIA trial will provide detailed insights into the anti-ischemic effects of ninerafaxstat in symptomatic patients with chronic coronary syndromes, including the burden of angina," said Juhani Knuuti, M.D., Ph.D., Professor and Director of Turku PET Centre in Turku, Finland and chief investigator of the IMPROVE-ISCHEMIA trial.
  • This could give physicians and patients an additional option to control angina symptoms without adversely impacting hemodynamics,” said Jai Patel, MRCP (U.K.), chief medical officer of Imbria.
  • “We look forward to sharing topline data from the trial in the fourth quarter of this year.”
    Imbria currently has two additional ongoing Phase 2 clinical trials with ninerafaxstat: IMPROVE-HCM, a randomized, placebo-controlled clinical trial in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) with topline data expected in the fourth quarter of 2023, and IMPROVE-DiCE, an open label clinical trial, which is currently enrolling patients with cardiometabolic heart failure with preserved ejection fraction (HFpEF) with interim data also expected in the fourth quarter of 2023.

Global Scleroderma Therapeutics Market Report 2023: Availability of a Range of Treatment Options Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 24, 2023
Health, Pharmaceutical, Tissue, Heart, Therapy, Prevalence, Human, Scar, Cyclophosphamide, Methotrexate, Research, Calcium channel, Inflammation, USD, Blood, ACE, Scleroderma, Autoimmune disease, Immune system, Organic acid, Agent handling, Collagen, Skin, Disease, Pharmaceutical industry

The "Global Scleroderma Therapeutics Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Scleroderma Therapeutics Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The value of the global scleroderma therapeutics market was USD 1.92 billion in 2022, driven by increasing prevalence of scleroderma, rising awareness about the disease across the globe.
  • The global scleroderma therapeutics market is driven by the increasing prevalence of scleroderma, rising awareness about the disease, and the availability of a range of treatment options.
  • The report gives an in-depth analysis of the key players involved in the global scleroderma therapeutics market.

Global Diabetic Neuropathic Pain Market Report to 2031: Players Include AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly and GlaxoSmithKline - ResearchAndMarkets.com

Retrieved on: 
Monday, May 15, 2023
Diabetes, Pharmaceutical, Health, Calcium channel, DNP, Gabapentinoid, Diagnosis, Analgesic, TCA, AGR, Serotonin, Serotonin–norepinephrine reuptake inhibitor, Therapy, Epidemiology, Patient, Investment, Dietary supplement, Pharmaceutical industry, Retail

Annualized diabetic neuropathic pain therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.

Key Points: 
  • Annualized diabetic neuropathic pain therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the diabetic neuropathic pain therapeutics market.
  • Analysis of the current and future market competition in the global diabetic neuropathic pain therapeutics market.
  • Develop business strategies by understanding the trends shaping and driving the global diabetic neuropathic pain therapeutics market.

Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2022 to 2027: Key Players Include Arena Pharmaceuticals, AstraZeneca, Bayer Aktiengesellschaft and Daiichi Sankyo - ResearchAndMarkets.com

Retrieved on: 
Friday, February 3, 2023
Pharmaceutical, Health, Cardiology, Diuretic, Anticoagulant, Fatigue, The, Endothelin receptor antagonist, Artery, Eras, Glycosidic bond, Swelling, CT, Pressure, Calcium channel, Hypertension, Heart, Growth, Pulmonary hypertension, Prevalence, COVID-19, Heart failure, PAH, Medical imaging, Pharmaceutical industry, Dietary supplement

Pulmonary arterial hypertension (PAH) refers to a life-threatening medical condition characterized by high blood pressure in the arteries that connect the heart to the lungs.

Key Points: 
  • Pulmonary arterial hypertension (PAH) refers to a life-threatening medical condition characterized by high blood pressure in the arteries that connect the heart to the lungs.
  • The increasing prevalence of cardiovascular and pulmonary disorders is one of the key factors driving the growth of the market.
  • The publisher provides an analysis of the key trends in each sub-segment of the global pulmonary arterial hypertension (PAH) drugs market report, along with forecasts at the global, regional and country level from 2022-2027.
  • Our report has categorized the market based on drug class, route of administration and end user.

Global Angina Pectoris Treatment Market Report 2022 to 2030 - Featuring Forest Laboratories, Gilead Sciences, GlaxoSmithKline, Novartis and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 31, 2023
Pharmaceutical, Health, Cardiology, II, III, Pfizer, Regeneron Pharmaceuticals, Tasly, Chest pain, Moyamoya disease, Enzyme, Calcium channel, Growth, Medical device, Pharmaceutical industry, Marketing, Alirocumab, Cilostazol, Ticagrelor, Angina

Thus, drug pipeline of angina pectoris treatment market comprises potential drugs which are specific and fast in therapeutic action.

Key Points: 
  • Thus, drug pipeline of angina pectoris treatment market comprises potential drugs which are specific and fast in therapeutic action.
  • The pipeline analysis for angina pectoris treatment market comprises projected market sales of Phase III drugs estimated till 2030.
  • What are the key micro and macro environmental factors that are impacting the growth of Angina Pectoris Treatment market?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Angina Pectoris Treatment market worldwide?

Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT

Retrieved on: 
Tuesday, November 29, 2022
COVID-19, Supraventricular tachycardia, Conference call, Dizziness, Adenosine, Revera, Syncope, Palpitations, Calcium channel, Perspiration, Pain, Safety, Baozou Big News Events, Patient, Fatigue, Pandemic, Anxiety, Paroxysmal attack, Paroxysmal supraventricular tachycardia, Webcast, Annual report, NDA, RAPID, Risk, PSVT, Atrial fibrillation, News, Clinical trial, SVT, Form 10-K, Lightheadedness, Pharmaceutical industry, Milestone, Conference

ET

Key Points: 
  • ET
    MONTREALandCHARLOTTE, N.C., Nov. 29, 2022 /PRNewswire/ --Milestone Pharmaceuticals Inc.(Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of the Company's management team will host a virtual commercial deep-dive event on Tuesday, December 6, 2022 at 1:00 p.m.
  • The event will focus on the commercial opportunity for etripamil, the Company's lead investigational product, for the treatment of patients with paroxysmal supraventricular tachycardia (PSVT).
  • To access a live or recorded webcast of the event and accompanying slides, please visit the News & Events section of Milestone's website at www.milestonepharma.com .
  • Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines.

Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022

Retrieved on: 
Tuesday, October 25, 2022
Paroxysmal supraventricular tachycardia, U.S. Securities and Exchange Commission, Education, Supraventricular tachycardia, SVT, Fatigue, Hospital, Pandemic, NDA, GA, Weill Cornell Medicine, PSVT, Patient, Palpitations, Clinical trial, Twitter, Division, Syncope, Annual report, Nasdaq, Time, Private Securities Litigation Reform Act, RAPID, Form 10-K, Company, Calcium channel, Pain, Research, NewYork-Presbyterian Hospital, Safety, Atrial fibrillation, Associate, Anxiety, Forward-looking statement, American Heart Association, Perspiration, COVID-19, Lightheadedness, Dizziness, Adenosine, Risk, Pharmaceutical industry, Cardiology, Milestone

Certain intravenous medications, including adenosine, beta-blockers and calcium channel blockers, have long been used for the acute treatment of PSVT.

Key Points: 
  • Certain intravenous medications, including adenosine, beta-blockers and calcium channel blockers, have long been used for the acute treatment of PSVT.
  • However, these medications must be administered under medical supervision, usually in an emergency department or other acute care setting.
  • Milestone is conducting a comprehensive development program for etripamil, with Phase 3 trials ongoing in paroxysmal supraventricular tachycardia (PSVT) and a Phase 2 proof-of-concept trial that is underway in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR).
  • Milestone Pharmaceuticals Inc.(Nasdaq: MIST) is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines.